Ginsenoside F1
Cat.No:IG0170 Solarbio
CAS:53963-43-2
Molecular Formula:C36H62O9
Molecular Weight:638.88
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > Ginsenoside F1CAS:53963-43-2
Molecular Formula:C36H62O9
Molecular Weight:638.88
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
| CAS | 53963-43-2 |
| Name | Ginsenoside F1 |
| Molecular Formula | C36H62O9 |
| Molecular Weight | 638.88 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
| MDL | MFCD06410947 |
| SMILES | C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO)([H])CC4)C |
| InChIKey | XNGXWSFSJIQMNC-FIYORUNESA-N |
| InChI | InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,45-31-29(43)28(42)27(41)23(18-37)44-31)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(40)32(3,4)30(33)22(39)17-35(24,34)7/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31-,33+,34+,35+,36-/m0/s1 |
| PubChem CID | 9809542 |
| Target Point | Cytochrome P450 |
| Passage | Metabolic Enzyme&Protease |
| Background | Ginsenoside F1 competitively inhibits CYP3A4. |
| Biological Activity | Ginsenoside F1 是 Ginsenoside Rg1 的酶促修饰衍生物,Ginsenoside F1 竞争性抑制 CYP3A4,对 CYP2D6 具有较弱的抑制作用。[1-2] |
| Data Literature Source | [1]. Wang DD, et al. Rare ginsenoside Ia synthesized from F1 by cloning and overexpression of the UDP-glycosyltransferase gene from Bacillus subtilis: synthesis, characterization, and in vitromelanogenesis inhibition activity in BL6B16 cells. J Ginseng Res. 2018 Jan; 42 (1) :42-49. [2]. Qin M, et al. Ginsenoside F1 Ameliorates Endothelial Cell Inflammatory Injury and Prevents Atherosclerosis in Mice through A20-Mediated Suppression of NF-kB Signaling. Front Pharmacol. 2017 Dec 22; 8:953 |
| Unit | Bottle |
| Specification | 5mg 10mM*1mL in DMSO 10mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download